Matias and Greg sit down with Brooks Leitner, the newest venture partner at PsyMed Ventures, to explore the future of brain and mental health investing. Brooks, an MD/PhD with deep experience from Yale and the NIH, shares his insights on how a human-first approach is reshaping neuroscience innovation and venture investing.
In this episode, we discuss:
- Broadening the Thesis: Evolving from a psychedelics-only focus to a comprehensive neuro investment strategy.
- Human-First Research: Shifting from animal models to clinical insights for better brain therapies.
- Key Investment Areas: Therapeutics, medical devices, diagnostics, consumer health, and AI-enabled care platforms.
- Early-Stage Conviction: Leveraging a prepared mind to spot breakthrough opportunities.
- Personal & Future Insights: Leadership challenges and the vision for the future of neuro investing.
Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner
Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank
